2021
Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases
Sarkar M, Brady CW, Fleckenstein J, Forde KA, Khungar V, Molleston JP, Afshar Y, Terrault NA. Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021, 73: 318-365. PMID: 32946672, DOI: 10.1002/hep.31559.Peer-Reviewed Original Research
2019
Tacrolimus and Indomethacin Are Safe and Effective at Reducing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography in Patients Who Have Undergone Liver Transplantation
Thiruvengadam NR, Forde KA, Chandrasekhara V, Ahmad NA, Ginsberg GG, Khungar V, Kochman ML. Tacrolimus and Indomethacin Are Safe and Effective at Reducing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography in Patients Who Have Undergone Liver Transplantation. Clinical Gastroenterology And Hepatology 2019, 18: 1224-1232.e1. PMID: 31622734, DOI: 10.1016/j.cgh.2019.10.014.Peer-Reviewed Original ResearchConceptsEndoscopic retrograde cholangiopancreatographyRisk of PEPDevelopment of PEPLiver transplantationTrough levelsBiliary complicationsIndomethacin useRectal indomethacinRetrospective studyRetrograde cholangiopancreatographyERCP proceduresOdds ratioMixed-effects multivariable logistic regressionEffectiveness of tacrolimusIncidence of PEPTacrolimus trough levelsCommon adverse eventsChronic kidney diseaseGlomerular filtration rateMultivariable logistic regressionRate of pancreatitisAddition of indomethacinChronic rejectionSevere PEPStable doseAn Advanced Practice Practitioner–Based Program to Reduce 30‐ and 90‐Day Readmissions After Liver Transplantation
Mahmud N, Halpern S, Farrell R, Ventura K, Thomasson A, Lewis H, Olthoff KM, Levine MH, Nazarian S, Khungar V. An Advanced Practice Practitioner–Based Program to Reduce 30‐ and 90‐Day Readmissions After Liver Transplantation. Liver Transplantation 2019, 25: 901-910. PMID: 30947393, PMCID: PMC6548546, DOI: 10.1002/lt.25466.Peer-Reviewed Original ResearchMeSH KeywordsAgedEnd Stage Liver DiseaseFemaleHumansLiver TransplantationMaleMiddle AgedNurse PractitionersPatient ReadmissionPilot ProjectsPostoperative CarePostoperative ComplicationsProfessional RoleProgram EvaluationRetrospective StudiesRisk FactorsSex FactorsTime FactorsTreatment OutcomeUnited StatesConceptsLiver transplantationReadmission ratesRisk factorsPostexposure groupCare programIndex hospitalization characteristicsRetrospective cohort studyRisk of readmissionHigher readmission ratesAssociated risk factorsAdvanced practice practitionersIndex hospitalizationAnalytic cohortCohort studyHospitalization characteristicsReferral centerHospital readmissionLT centersAdjusted analysisMale sexNurse practitionersReadmissionClinic availabilitySignificant differencesPatients
2017
Safety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV‐TARGET study
Saxena V, Khungar V, Verna EC, Levitsky J, Brown RS, Hassan MA, Sulkowski MS, O'Leary JG, Koraishy F, Galati JS, Kuo AA, Vainorius M, Akushevich L, Nelson DR, Fried MW, Terrault N, Reddy KR. Safety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV‐TARGET study. Hepatology 2017, 66: 1090-1101. PMID: 28504842, PMCID: PMC5756478, DOI: 10.1002/hep.29258.Peer-Reviewed Original ResearchConceptsSustained virologic responseOmbitasvir/paritaprevir/ritonavirParitaprevir/ritonavirTransplant recipientsLiver transplantKidney transplantAntiviral therapyLarge prospective observational cohort studyChronic hepatitis C virusLiver-kidney transplant recipientsProspective observational cohort studySolid organ transplant recipientsHepatitis C virus (HCV) treatmentBaseline total bilirubinHCV-TARGET studyPrior antiviral therapyAbsence of cirrhosisKidney transplant recipientsLiver transplant recipientsObservational cohort studyOrgan transplant recipientsC virus treatmentGlomerular filtration rateCessation of treatmentSOF/ledipasvir
2010
Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma
Yu JC, Neugut AI, Wang S, Jacobson JS, Ferrante L, Khungar V, Lim E, Hershman DL, Brown RS, Siegel AB. Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma. Cancer 2010, 116: 1801-1809. PMID: 20143441, PMCID: PMC3664455, DOI: 10.1002/cncr.24936.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaAdvanced diseaseCox modelMultivariable logistic regression modelColumbia University Medical CenterReceipt of transplantationPredictors of mortalityAmerican Cancer SocietyUniversity Medical CenterReceipt of transplantLogistic regression modelsLiver transplantTransplant recipientsConsecutive patientsMore patientsBlack patientsHispanic patientsPoor prognosisHCC patientsInsurance statusPoor survivalMedicaid patientsCancer SocietyMedical CenterMedicaid recipients